CRVS missed EPS expectations by 404.63%
Nov 22, 2024, 11:32 PM
-1.96%
What does CRVS do
Corvus Pharmaceuticals, a clinical-stage biopharmaceutical company based in Burlingame, California, develops immune modulators for cancers and autoimmune diseases, with key products including soquelitinib and ciforadenant. Founded in 2016, it employs 28 people and focuses on innovative immunotherapy approaches.
Corvus Pharmaceuticals (CRVS) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Corvus Pharmaceuticals's actual EPS was -$0.60, missing the estimate of -$0.12 per share, resulting in a -404.63% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.